Clinical Evaluation of Approved and Investigational Contact Lenses Using New UV Additive

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02982018

Enrollment

133

Registered

2016-12-05

Start date

2016-10-01

Completion date

2017-02-18

Last updated

2018-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Acuity

Brief summary

Randomized, 8-visit dispensing study over 14 weeks to evaluate the safety and efficacy of an investigational contact lens with a new UV blocker compared to a marketed contact lens.

Interventions

DEVICEsenofilcon A with new UV blocker

Investigational Contact Lens

DEVICEsenofilcon A

J&J Marketed Contact Lens

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. The subject must read and sign the Informed Consent form. 2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Healthy adult males or females age ≥ 18 years of age with signed informed consent. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them. 4. The subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 6.00 Diopters (D). 5. The subject's refractive cylinder must be ≤ 1.00 D in each eye. 6. The subject must have visual acuity best correctable to 20/25+3 or better for each eye. 7. Subjects should own a wearable pair of spectacles. 8. The subject is a current spherical soft contact lens wearer (defined as a minimum of 6 hours of Daily Wear per day, at least 5 days per week, for a minimum of 1 month prior to the study) and willing to wear the study lenses on a similar basis. 9. Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week. 10. The subject must have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion criteria

1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued). 2. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis). 3. Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, oral (e.g. Seldane, Chlor-Trimeton, and Benadryl) and ophthalmic antihistamines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), oral and ophthalmic Beta-adrenergic blockers (e.g., Propranolol, Timolol, and Practolol), systemic steroids, and any prescribed or over the counter (OTC) ocular medication. 4. Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry. 5. Any previous, or planned, ocular or interocular surgery (e.g.., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.). 6. Any grade 2 or greater slit lamp findings (e.g.., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g.., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear. 7. Any known hypersensitivity or allergic reaction to Optifree®Puremoist® multi-purpose care solution or Eye-Cept® rewetting drop solution. 8. Any ocular infection, allergy or clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca, ocular hypertension), or ocular conditions (e.g. strabismus), which might interfere with the study. 9. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. 10. Toric, extended wear, monovision or multi-focal contact lens correction. 11. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment. 12. History of binocular vision abnormality or strabismus. 13. Employee or relative of employees of sponsor or investigational clinic (e.g., Investigator, Coordinator, Technician).

Design outcomes

Primary

Measure	Time frame	Description
Eyestrain Related to Glare	Up to 12-Week Follow-up	Eyestrain related to glare was assessed at the 2-, 4-, 8- and 12- week follow-up visits using an 11-item questionnaire. This questionnaire assesses patient-experience attributes of soft contact lenses. Derived eyestrain related to glare scores using Item Response Theory (IRT) follow a normal distribution with a mean of 50 and a standard deviation of 10. Scores in this study ranged from 30 to 70. Lower scores indicate better performance. This questionnaire is still under development and the data collected is considered exploratory.
Distance Monocular logMAR Visual Acuity (VA)	Up to 12-Week Follow-up	Distance logMAR Visual Acuity was assessed for each subject and eye at 2-, 4- 8- and 12-weeks. The average logMAR visual acuity for each lens and time point was reported. Lower values of logMAR indicate better vision.
Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings	Up to 12-Week Follow-up	Slit lamp findings were graded using a FDA Grade Scale, 0 = None, 1 = Slight, 2 = Moderate, 3 = Significant, 4 = Advanced. Measurements were taken in each subject eye at the initial visit, 2-4-8- and 12-week follow-ups. A new response variable was derived by dichotomizing the data as follows: 1 if a Grade 3or higher SLF was observed and 0 otherwise. The Percentage of eyes with Grade 3 or higher SLFs was reported for each lens and time point.

Secondary

Measure	Time frame	Description
Contact Lens Wearing Time	Up to 12-Week Follow-up	Contact lens wearing time (hours) was self-reported by each subject at the 2-, 4-, 8- and 12-week follow-ups. The average contact lens wearing time (hours) for each lens and time point was reported.
Percentage of Eyes With Subject Reported Symptoms Problems or Complaints	Up to 12-Week Follow-up	Symptoms, problems and complaints are subject reported and were collected for each subject eye at the 1-, 2-, 4-, 8- and 12-week follow-up evaluations. The data is reported as a binary outcome of yes if a subject experience a problem or complaint or no otherwise. Symptoms, problems and complaints include the following: Burning/Stinging, Itchiness/Scratchiness, Dryness, Lens Awareness, Grittiness/Foreign Body Sensation, Redness, Irritation/Discomfort, Cloudy/Blurry/Hazy, Variable Vision and Other The Percentage of subjects eyes with symptoms, problems or complaints was reported for each lens and time point.

Countries

United States

Participant flow

Recruitment details

A total of 133 subjects were enrolled into the study. Of the enrolled subjects 131 were dispensed study lenses and 2 subjects failed to meet the eligibility criteria. Of the dispensed subjects 123 completed the study and 8 subjects were discontinued.

Participants by arm

Arm	Count
Senofilcon A With New UV Blocker Subjects that wore the senofilcon A with new UV blocker lens throughout the entire duration of the study.	67
Senofilcon A Subjects that wore the senofilcon A lens throughout the entire duration of the study.	64
Total	131

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Adverse Event	1	1
Overall Study	Incorrect Lens Dispensed	1	0
Overall Study	Lens Discomfort	2	0
Overall Study	Protocol Violation	1	1
Overall Study	Withdrawal by Subject	0	1

Baseline characteristics

Characteristic	Senofilcon A With New UV Blocker	Senofilcon A	Total
Age, Continuous	31.2 Years STANDARD_DEVIATION 8.15	32.1 Years STANDARD_DEVIATION 7.99	31.6 Years STANDARD_DEVIATION 8.02
Race/Ethnicity, Customized Asian	6 Participants	1 Participants	7 Participants
Race/Ethnicity, Customized Black or African American	4 Participants	1 Participants	5 Participants
Race/Ethnicity, Customized Other	1 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized White	56 Participants	62 Participants	118 Participants
Sex: Female, Male Female	45 Participants	47 Participants	92 Participants
Sex: Female, Male Male	22 Participants	17 Participants	39 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	0 / 67	0 / 64
other Total, other adverse events	0 / 67	0 / 64
serious Total, serious adverse events	0 / 67	0 / 64

Outcome results

Primary

Distance Monocular logMAR Visual Acuity (VA)

Distance logMAR Visual Acuity was assessed for each subject and eye at 2-, 4- 8- and 12-weeks. The average logMAR visual acuity for each lens and time point was reported. Lower values of logMAR indicate better vision.